COGNITION THERAPEUTICS INC. - COMMON STOCK

Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023

21 3 2023 08:00:32 提供 Nasdaq GlobeNewswire

UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

16 3 2023 12:18:55 提供 Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

16 3 2023 07:30:53 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

15 3 2023 07:30:16 提供 Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference

07 3 2023 08:00:13 提供 Nasdaq GlobeNewswire

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

22 2 2023 08:00:02 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia

21 2 2023 07:30:49 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

09 2 2023 08:00:38 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease

22 12 2022 08:00:46 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"

21 12 2022 16:05:00 提供 Nasdaq GlobeNewswire

First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812

15 12 2022 08:00:42 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

01 12 2022 07:30:00 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD

28 11 2022 08:00:01 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series

21 11 2022 08:00:33 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Announces Closing of Public Offering

15 11 2022 12:55:47 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

14 11 2022 08:00:07 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Announces Pricing of Public Offering

10 11 2022 08:00:01 提供 Nasdaq GlobeNewswire

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

12 10 2022 08:00:01 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

11 10 2022 08:00:01 提供 Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference

29 9 2022 07:30:00 提供 Nasdaq GlobeNewswire